European Radiology:活体肝移植中胆管-管吻合术后胆道狭窄的经皮经肝治疗方法

2022-06-10 shaosai MedSci原创

在活体肝移植(LDLT)中重建胆管时,由于胆管-管吻合术保留了Oddi括约肌并保持了生理上的胆肠连续性,因此比肝空肠吻合术更受欢迎。

肝移植是治疗终末期肝病或小型肝细胞癌(HCC)的标准治疗方法。由于器官的短缺仍然是一个严峻的问题,因此活体肝移植(LDLT)目前被认为是一种可供选择的治愈性治疗方式。在成人LDLT中重建胆管时,由于胆管-管吻合术保留了Oddi括约肌并保持了生理上的胆肠连续性,因此比肝空肠吻合术更受欢迎。然而,与肝空肠吻合术相比,胆管-管吻合术更经常发生胆道狭窄。

近日,发表在European Radiology杂志的一项研究探讨了LDLT中胆管-管吻合术后经皮经肝治疗胆道狭窄的临床效果。

项回顾性研究利用患者的医疗记录和图像,记录每位患者的基线特征、手术细节、临床结果、8个月内引流导管移除率以及导管移除后的复发情况。通过单变量和多变量分析,评估了8个月内引流导管拔除失败和引流导管拔除后胆道狭窄复发的风险因素。 

本研究共评估了112名患者(53.4±8.79岁,91名男性)。75名患者(70.0%)放置了多个引流导管。107名患者(95.5%)成功拔出引流导管。引流导管在8个月内未能移除与肝动脉并发症(p = 0.034)和需要替代通道技术的狭窄(p = 0.034)有关。在1、2、3和5年内,拔除引流导管后的累积初级通畅率分别为85.4%、79.8%、75.8%和68.4%。胆道狭窄的复发与存在未经治疗的孤立扇形管(aHR,3.632;95% CI,1.086-12.150,p = 0.037)和同时存在的胆漏(aHR,2.475;95% CI,1.090-5.621,p = 0.031)有关。 


图 本研究中使用的导管到导管的胆道吻合术的类型

本研究表明,经皮经肝治疗对治疗LDLT中胆管-管吻合术后的胆道狭窄具有很大的临床前景。由于这些患者经常发生多处胆管的狭窄,因此需要进行多次引流以保持胆管畅通。

 

原文出处:

In Joon Lee,Jae Hwan Lee,Seong Hoon Kim,et al.Percutaneous transhepatic treatment for biliary stricture after duct-to-duct biliary anastomosis in living donor liver transplantation: a 9-year single-center experience.DOI:10.1007/s00330-021-08373-z

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (4)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=2066477, encodeId=4ba520664e762, content=<a href='/topic/show?id=37643946566' target=_blank style='color:#2F92EE;'>#吻合术#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=39465, encryptionId=37643946566, topicName=吻合术)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=33b92500139, createdName=12498b37m72暂无昵称, createdTime=Mon Jan 16 17:30:59 CST 2023, time=2023-01-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1729607, encodeId=f0271e2960728, content=<a href='/topic/show?id=986913980dd' target=_blank style='color:#2F92EE;'>#PE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13980, encryptionId=986913980dd, topicName=PE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f06c33759375, createdName=feather89, createdTime=Thu Aug 04 21:30:59 CST 2022, time=2022-08-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1399318, encodeId=48751399318f0, content=<a href='/topic/show?id=cac364650c0' target=_blank style='color:#2F92EE;'>#治疗方法#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=64650, encryptionId=cac364650c0, topicName=治疗方法)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8cec2200006, createdName=showtest, createdTime=Wed Jun 08 04:30:59 CST 2022, time=2022-06-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1628517, encodeId=8c91162851ec2, content=<a href='/topic/show?id=9a4e83503e4' target=_blank style='color:#2F92EE;'>#胆管#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=83503, encryptionId=9a4e83503e4, topicName=胆管)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c21721182790, createdName=cmj15wellington, createdTime=Wed Jun 08 04:30:59 CST 2022, time=2022-06-08, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=2066477, encodeId=4ba520664e762, content=<a href='/topic/show?id=37643946566' target=_blank style='color:#2F92EE;'>#吻合术#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=39465, encryptionId=37643946566, topicName=吻合术)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=33b92500139, createdName=12498b37m72暂无昵称, createdTime=Mon Jan 16 17:30:59 CST 2023, time=2023-01-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1729607, encodeId=f0271e2960728, content=<a href='/topic/show?id=986913980dd' target=_blank style='color:#2F92EE;'>#PE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13980, encryptionId=986913980dd, topicName=PE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f06c33759375, createdName=feather89, createdTime=Thu Aug 04 21:30:59 CST 2022, time=2022-08-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1399318, encodeId=48751399318f0, content=<a href='/topic/show?id=cac364650c0' target=_blank style='color:#2F92EE;'>#治疗方法#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=64650, encryptionId=cac364650c0, topicName=治疗方法)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8cec2200006, createdName=showtest, createdTime=Wed Jun 08 04:30:59 CST 2022, time=2022-06-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1628517, encodeId=8c91162851ec2, content=<a href='/topic/show?id=9a4e83503e4' target=_blank style='color:#2F92EE;'>#胆管#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=83503, encryptionId=9a4e83503e4, topicName=胆管)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c21721182790, createdName=cmj15wellington, createdTime=Wed Jun 08 04:30:59 CST 2022, time=2022-06-08, status=1, ipAttribution=)]
    2022-08-04 feather89
  3. [GetPortalCommentsPageByObjectIdResponse(id=2066477, encodeId=4ba520664e762, content=<a href='/topic/show?id=37643946566' target=_blank style='color:#2F92EE;'>#吻合术#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=39465, encryptionId=37643946566, topicName=吻合术)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=33b92500139, createdName=12498b37m72暂无昵称, createdTime=Mon Jan 16 17:30:59 CST 2023, time=2023-01-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1729607, encodeId=f0271e2960728, content=<a href='/topic/show?id=986913980dd' target=_blank style='color:#2F92EE;'>#PE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13980, encryptionId=986913980dd, topicName=PE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f06c33759375, createdName=feather89, createdTime=Thu Aug 04 21:30:59 CST 2022, time=2022-08-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1399318, encodeId=48751399318f0, content=<a href='/topic/show?id=cac364650c0' target=_blank style='color:#2F92EE;'>#治疗方法#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=64650, encryptionId=cac364650c0, topicName=治疗方法)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8cec2200006, createdName=showtest, createdTime=Wed Jun 08 04:30:59 CST 2022, time=2022-06-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1628517, encodeId=8c91162851ec2, content=<a href='/topic/show?id=9a4e83503e4' target=_blank style='color:#2F92EE;'>#胆管#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=83503, encryptionId=9a4e83503e4, topicName=胆管)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c21721182790, createdName=cmj15wellington, createdTime=Wed Jun 08 04:30:59 CST 2022, time=2022-06-08, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=2066477, encodeId=4ba520664e762, content=<a href='/topic/show?id=37643946566' target=_blank style='color:#2F92EE;'>#吻合术#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=39465, encryptionId=37643946566, topicName=吻合术)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=33b92500139, createdName=12498b37m72暂无昵称, createdTime=Mon Jan 16 17:30:59 CST 2023, time=2023-01-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1729607, encodeId=f0271e2960728, content=<a href='/topic/show?id=986913980dd' target=_blank style='color:#2F92EE;'>#PE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13980, encryptionId=986913980dd, topicName=PE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f06c33759375, createdName=feather89, createdTime=Thu Aug 04 21:30:59 CST 2022, time=2022-08-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1399318, encodeId=48751399318f0, content=<a href='/topic/show?id=cac364650c0' target=_blank style='color:#2F92EE;'>#治疗方法#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=64650, encryptionId=cac364650c0, topicName=治疗方法)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8cec2200006, createdName=showtest, createdTime=Wed Jun 08 04:30:59 CST 2022, time=2022-06-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1628517, encodeId=8c91162851ec2, content=<a href='/topic/show?id=9a4e83503e4' target=_blank style='color:#2F92EE;'>#胆管#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=83503, encryptionId=9a4e83503e4, topicName=胆管)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c21721182790, createdName=cmj15wellington, createdTime=Wed Jun 08 04:30:59 CST 2022, time=2022-06-08, status=1, ipAttribution=)]

相关资讯

BMC Gastroenterology:医疗单位年度肝移植手术量与患者术后死亡率的关系

肝移植 (LT) 是一项重大而、困难的手术,需要涉及多个医疗团队进行相互配合。活体肝移植与移植后手术并发症较高,住院死亡率介于3.6至18.9%之间。

JAMA Surg:禁酒6个月 vs 提前肝移植对酒精相关肝病患者预后的影响

对于准备接受肝移植的酒精相关肝病患者,严格的6个月以上禁酒不会对患者预后产生重要影响

JGH: 循环线粒体 DNA 水平升高可预测肝移植后患者的早期同种异体移植物功能障碍

线粒体(mitochondrion)是一种存在于大多数细胞中的由两层膜包被的细胞器,是细胞中制造能量的结构,是细胞进行有氧呼吸的主要场所

一出手即降低肝细胞癌术后1、3、5年复发风险近8成!这个“神药”是真全能!

研究表明,他汀类药物的使用与肝手术后肝细胞癌复发的减少有关

Oral Dis:龋齿与肝移植有关吗?一项系统回顾和荟萃分析

在肝衰竭的病人进行肝脏移植治疗期间,口腔卫生困难以及唾液和口腔微生物菌群的变化可能会增加牙齿生物膜的致病潜力。

2022 ASCO:通过个性化和肿瘤知情的ctDNA检测监测肝细胞癌患者肝脏移植后疾病复发的可行性

证明ctDNA检测用于监测以治愈为目的接受肝移植的HCC患者复发的可行性。